Cargando…
Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN‐amplified neuroblastoma cells
MYCN gene amplification is consistently associated with poor prognosis in patients with neuroblastoma, a pediatric tumor arising from the sympathetic nervous system. Conventional anticancer drugs, such as alkylating agents and platinum compounds, have been used for the treatment of high‐risk patient...
Autores principales: | Yamashita, Ken, Kiyonari, Shinichi, Tsubota, Shoma, Kishida, Satoshi, Sakai, Ryuichi, Kadomatsu, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385364/ https://www.ncbi.nlm.nih.gov/pubmed/32415892 http://dx.doi.org/10.1111/cas.14485 |
Ejemplares similares
-
SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2016) -
Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2014) -
Origin and mechanism of neuroblastoma
por: Tsubota, Shoma, et al.
Publicado: (2017) -
Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes
por: Su, Zhendong, et al.
Publicado: (2017) -
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
por: Blackledge, G.
Publicado: (1998)